Medical detox and treatment programs focus on: Stabilizing the body safely Managing withdrawal symptoms with oversight Supporting sleep, nutrition, and mental health Medications like: Buprenorphine Methadone Naltrexone Have strong evidence showing they: Reduce cravings Lower overdose risk Improve long-term outcomes Sleep and stress, which DSIP targets, are also addressed through: Structured care Therapy Medication when appropriate Routine and stabilization A Better Way to Look at It DSIP is interesting from a research perspective
Collectively, these findings indicate that BPC-157 may support neural resilience and neurotransmitter homeostasis in experimental models
J Physiol Paris 91:173178 Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M et al (1993) A new gastric juice peptide, BPC
Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results
All 32 participants completed the study
